154 related articles for article (PubMed ID: 26283228)
1. Bio-Distribution, Imaging Protocols and Diagnostic Accuracy of PET with Tracers of Lipogenesis in Imaging Prostate Cancer: a Comparison between 11C-Choline, 18FFluoroethylcholine and 18F-Methylcholine.
Calabria F; Gallo G; Schillaci O; Cascini GL
Curr Pharm Des; 2015; 21(32):4738-47. PubMed ID: 26283228
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. PET/CT with
Calabria F; Chiaravalloti A; Cicciò C; Gangemi V; Gullà D; Rocca F; Gallo G; Cascini GL; Schillaci O
Nucl Med Biol; 2017 Aug; 51():40-54. PubMed ID: 28575697
[TBL] [Abstract][Full Text] [Related]
4. Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients: physiological distribution, statistical differences, imaging pearls, and normal variants.
Haroon A; Zanoni L; Celli M; Zakavi R; Beheshti M; Langsteger W; Fanti S; Emberton M; Bomanji J
Nucl Med Commun; 2015 Nov; 36(11):1065-75. PubMed ID: 26340086
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F]fluorocholine ([18F]dOC).
Henriksen G; Herz M; Hauser A; Schwaiger M; Wester HJ
Nucl Med Biol; 2004 Oct; 31(7):851-8. PubMed ID: 15464386
[TBL] [Abstract][Full Text] [Related]
6. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
7. Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis.
Ouyang Q; Duan Z; Lei J; Jiao G
Tumour Biol; 2016 Mar; 37(3):2999-3007. PubMed ID: 26415734
[TBL] [Abstract][Full Text] [Related]
8. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer.
Schillaci O; Calabria F; Tavolozza M; Cicciò C; Carlani M; Caracciolo CR; Danieli R; Orlacchio A; Simonetti G
Nucl Med Commun; 2010 Jan; 31(1):39-45. PubMed ID: 19972635
[TBL] [Abstract][Full Text] [Related]
9. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.
Picchio M; Messa C; Landoni C; Gianolli L; Sironi S; Brioschi M; Matarrese M; Matei DV; De Cobelli F; Del Maschio A; Rocco F; Rigatti P; Fazio F
J Urol; 2003 Apr; 169(4):1337-40. PubMed ID: 12629355
[TBL] [Abstract][Full Text] [Related]
10. Influence of Four Radiotracers in PET/CT on Diagnostic Accuracy for Prostate Cancer: A Bivariate Random-Effects Meta-Analysis.
Liu J; Chen Z; Wang T; Liu L; Zhao L; Guo G; Wang D
Cell Physiol Biochem; 2016; 39(2):467-80. PubMed ID: 27383216
[TBL] [Abstract][Full Text] [Related]
11. 11C/ 18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended?
Nanni C; Castellucci P; Farsad M; Rubello D; Fanti S
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1704-5. PubMed ID: 17619877
[No Abstract] [Full Text] [Related]
12. 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.
Brogsitter C; Zöphel K; Kotzerke J
Eur J Nucl Med Mol Imaging; 2013 Jul; 40 Suppl 1():S18-27. PubMed ID: 23579863
[TBL] [Abstract][Full Text] [Related]
13. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
[TBL] [Abstract][Full Text] [Related]
14. PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.
Fanti S; Minozzi S; Castellucci P; Balduzzi S; Herrmann K; Krause BJ; Oyen W; Chiti A
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):55-69. PubMed ID: 26450693
[TBL] [Abstract][Full Text] [Related]
15. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
von Eyben FE; Kairemo K
Ann Nucl Med; 2016 Jul; 30(6):385-92. PubMed ID: 27173771
[TBL] [Abstract][Full Text] [Related]
16. The future of choline PET in the era of prostate specific membrane antigen.
Evangelista L; Cuppari L; Zattoni F; Mansi L; Bombardieri E
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):19-28. PubMed ID: 29383928
[TBL] [Abstract][Full Text] [Related]
17. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis.
Evangelista L; Guttilla A; Zattoni F; Muzzio PC; Zattoni F
Eur Urol; 2013 Jun; 63(6):1040-8. PubMed ID: 23036576
[TBL] [Abstract][Full Text] [Related]
18. The optimal timing to perform 18F/11C-choline PET/CT in patients with suspicion of relapse of prostate cancer: trigger PSA versus PSA velocity and PSA doubling time.
Calabria F; Rubello D; Schillaci O
Int J Biol Markers; 2014 Dec; 29(4):e423-30. PubMed ID: 24474456
[TBL] [Abstract][Full Text] [Related]
19. Colchicine must be stopped before imaging with [18F]-methylcholine PET/CT.
Roef MJ; van der Poel H; van der Laken CJ; Vogel WV
Nucl Med Commun; 2010 Dec; 31(12):1075-7. PubMed ID: 21089227
[TBL] [Abstract][Full Text] [Related]
20. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
